Quick Answer
Veradermics, Inc reported Net Income of -$70.00 million for fiscal year 2025.
Veradermics, Inc — Key Financials by Year
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net Income | -$70.00M -164.3% |
-$26.49M | — |
| Diluted EPS | -$111.91 -202.1% |
-$37.05 | — |
| Total Assets | $152.62M +174.8% |
$55.53M | — |
| Cash and Equivalents | $21.77M -59.0% |
$53.08M | — |
| Stockholders Equity | -$121.01M -149.6% |
-$48.48M -118.0% |
-$22.24M |
| R&D Expense | $62.06M +166.6% |
$23.28M | — |
| Operating Income | -$72.35M -170.2% |
-$26.78M | — |
| Shares Outstanding | 749,760 +1.7% |
736,933 | — |
- Veradermics, Inc reported Net Income of -$70.00 million for fiscal year 2025.
- Veradermics, Inc showed a decrease of -164.3% in Net Income compared to the prior fiscal year.
- Veradermics, Inc reported Diluted EPS of $111.91 per share (loss) for fiscal year 2025.
- Veradermics, Inc showed a decrease of -202.1% in Diluted EPS compared to the prior fiscal year.
- Veradermics, Inc reported Total Assets of $152.62 million for fiscal year 2025.
- Veradermics, Inc showed an increase of +174.8% in Total Assets compared to the prior fiscal year.
- Veradermics, Inc reported Cash and Equivalents of $21.77 million for fiscal year 2025.
- Veradermics, Inc showed a decrease of -59.0% in Cash and Equivalents compared to the prior fiscal year.
- Veradermics, Inc reported Stockholders Equity of -$121.01 million for fiscal year 2025.
- Veradermics, Inc showed a decrease of -149.6% in Stockholders Equity compared to the prior fiscal year.
- Veradermics, Inc reported R&D Expense of $62.06 million for fiscal year 2025.
- Veradermics, Inc showed an increase of +166.6% in R&D Expense compared to the prior fiscal year.
- Veradermics, Inc reported Operating Income of -$72.35 million for fiscal year 2025.
- Veradermics, Inc showed a decrease of -170.2% in Operating Income compared to the prior fiscal year.
- Veradermics, Inc reported Shares Outstanding of 749.8 thousand shares for fiscal year 2025.
- Veradermics, Inc showed an increase of +1.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: